Publications
63
Citations
1,487
Est. group size
—
Recurring co-author estimate
Active years
26
Publishing since 2000
This researcher's work centers on blood cancers, particularly chronic lymphocytic leukemia (CLL), investigating how drug combinations and cell-signaling pathways affect cancer cell survival and death. Additional projects touch on cardiac side effects of cancer drugs, protein modification in inflammation, and other topics in molecular and clinical medicine. The work combines laboratory studies of cancer cell biology with some clinical case reports and broader biochemical mechanisms.
Publication output has grown unevenly over the past decade, with a notable peak in 2023 followed by more modest but continued output through 2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Exploring the mechanism of action of trastuzumab-induced cardiomyocyte atrophy based on the FN1/PI3K/AKT-mediated mTOR-independent signaling pathway
Genomics · 2025
- Protein palmitoylation: an emerging regulator of inflammatory signaling and diseases
Frontiers in Immunology · 2025
- The Effect of NTCP Deficiency in Pregnancy on Maternal and Fetal Outcomes: A Case-control Study Based on SLC10A1 Genetic Analysis
SSRN Electronic Journal · 2025
- Abstract B126: The effects of Amaryllidaceae plant constituents narciclasine, lycorine and haemanthamine on chronic lymphocytic leukemia cells
Molecular Cancer Therapeutics · 2025
- Abstract 518: The CDK2/9 inhibitor fadraciclib is active in Richter transformation and lymphoma cell lines by targeting both cell survival and proliferation
Cancer Research · 2024
- Osthole protects H9c2 cardiomyocytes against trastuzumab-induced damage by enhancing autophagy through the p38MAPK/mTOR signaling pathway
Toxicology in Vitro · 2023
- Supplementary Figure 1 from Killing of Chronic Lymphocytic Leukemia by the Combination of Fludarabine and Oxaliplatin Is Dependent on the Activity of XPF Endonuclease
2023
- Supplementary Table 1 from Killing of Chronic Lymphocytic Leukemia by the Combination of Fludarabine and Oxaliplatin Is Dependent on the Activity of XPF Endonuclease
2023
- Supplementary Figure 2 from Killing of Chronic Lymphocytic Leukemia by the Combination of Fludarabine and Oxaliplatin Is Dependent on the Activity of XPF Endonuclease
2023
- Supplementary Table 2 from Killing of Chronic Lymphocytic Leukemia by the Combination of Fludarabine and Oxaliplatin Is Dependent on the Activity of XPF Endonuclease
2023
- Data from Killing of Chronic Lymphocytic Leukemia by the Combination of Fludarabine and Oxaliplatin Is Dependent on the Activity of XPF Endonuclease
2023
- Data from Killing of Chronic Lymphocytic Leukemia by the Combination of Fludarabine and Oxaliplatin Is Dependent on the Activity of XPF Endonuclease
2023
- Supplementary Figure 2 from Killing of Chronic Lymphocytic Leukemia by the Combination of Fludarabine and Oxaliplatin Is Dependent on the Activity of XPF Endonuclease
2023
- Supplementary Table 2 from Killing of Chronic Lymphocytic Leukemia by the Combination of Fludarabine and Oxaliplatin Is Dependent on the Activity of XPF Endonuclease
2023
- Supplementary Table 1 from Killing of Chronic Lymphocytic Leukemia by the Combination of Fludarabine and Oxaliplatin Is Dependent on the Activity of XPF Endonuclease
2023
- Cancer Research×4
- Leukemia×2
- Neuro-Oncology×2
- Gastroenterology×1
- Proceedings of the National Academy of Sciences×1
- Michael R. Grever
Medicine · The Ohio State University
- John Alan Gambril
Medicine · The Ohio State University
- Lindsay Rosen
Medicine · The Ohio State University
- Sunnia T. Chen
Medicine · The Ohio State University
- James S. Blachly
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile